The board of directors of Sino Biopharmaceutical Limited announced that "Dexmedetomidine Hydrochloride Injection", an intravenous anesthetic developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the People's Republic of China. The product is filed as a Chemicals Category 3 drug and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs. Dexmedetomidine is an 2 adrenergic receptor agonist with central sympathetic inhibition, anxiolytic and sedative effects; it can be used in general anesthesia, sedation for endotracheal intubation during ventilator treatment and for invasive examinations, as well as cardiovascular surgery anesthesia and perioperative anesthesia combined with other drugs. Dexmedetomidine does not cause respiratory depression during sedation and hypnosis. It is recommended by many domestic and international guidelines and has been included in the national medical insurance, and is one of the mainstream anesthetic drugs in clinical practice. The approval for launch of this product will strengthen the Group's strength in the field of anesthesia.